Company Focus
Novo Nordisk
Latest Novo Nordisk News
Pharmaceutical
Novo Nordisk has reported new Phase IIIb data showing its GLP-1 drug semaglutide, in both oral and injectable forms, led to significant health benefits in adults with type 2 diabetes facing cardiovascular complications. 31 March 2025
Related News
Insights
Company Spotlight
Privately-held GAIA is focused on the development of evidence-based, safe and accessible AI-powered digital therapeutics (DTx) that help patients restore and maintain their mental and physical health.
Latest News & Features of interest to Novo Nordisk
Biotechnology
US healthcare giant Johnson & Johnson’s venture capital arm has made its first investment in South Korea, leading a $20 million series B financing round for Prazer Therapeutics, a biotech focused on targeted protein degradation. 2 April 2025
Pharmaceutical
Danish biotech Gubra saw its share gains more than 8% to 448.00 kroner, after it announced positive results from the single ascending dose (SAD) Phase I clinical trial with the long-acting amylin analogue GUBamy (GUB014295). 2 April 2025
Pharmaceutical
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, untreated Parkinson’s disease, that failed to meet the primary endpoint of the study. 2 April 2025
Pharmaceutical
The European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to radiprodil, an investigational, potent negative allosteric modulator selectively targeting the N-methyl-D-aspartate receptor subtype 2B (NR2B or GluN2B), for the treatment of GRIN-related neurodevelopmental disorder (NDD), from neurodevelopmental disorders company GRIN Therapeutics. 2 April 2025
Biotechnology
Olga Uspenskaya-Cado has been named chief medical officer (CMO) of VectorY Therapeutics, a privately-held Dutch biotech advancing vectorized antibody therapies for neurodegenerative diseases. 1 April 2025
Pharmaceutical
US drug developer Palatin Technologies announced that its BMT-801 Phase II obesity co-administration study met its primary endpoint and was highly statistically significant. 1 April 2025
Pharmaceutical
Positive results from the PURSUIT Phase IIb trial of AstraZeneca’s AZD0780 have shown a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo. 1 April 2025
Pharmaceutical
New data from Israel-based generics giant Teva Pharmaceutical Industries show favorable patient and healthcare provider experiences with TEV-‘749, a long-acting injectable formulation of olanzapine. 1 April 2025
Biotechnology
Eisai and Biogen today provided an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab – trade name Leqembi - as a treatment for early AD (mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD)) by the European Commission (EC). 1 April 2025
Pharmaceutical
Merck & Co -as announced the first presentation of full results from the Phase III ZENITH trial of Winrevair (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension World Health Organization functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. 1 April 2025
Latest In Brief for Novo Nordisk
Latest Related Ones To Watch News
Japanese drugmaker Otsuka Holdings’ subsidiary Taiho Pharmaceuticals is to buy Araris Biotech, a Swiss oncology firm developing antibody drug conjugates (ADCs). 17 March 2025
11 March 2025
11 February 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze